硼替佐米用于预防和治疗致敏患者的排斥反应。
Use of bortezomib for prevention and treatment of rejection in sensitized patients.
作者信息
Hartono Choli, Lubetzky Michelle, Aull Meredith J, Saal Stuart, Figueiro Jose, Kapur Sandip, Dadhania Darshana
机构信息
Department of Transplantation Medicine, Weill Cornell Medical College/New York-Presbyterian Hospital, New York, New York, USA.
出版信息
Clin Transpl. 2009:499-503.
We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.
我们报告了2例致敏患者，他们接受硼替佐米治疗后成功降低了供体特异性抗体（DSA）。我们的病例说明了包括硼替佐米在内的联合治疗对高致敏患者急性抗体介导排斥反应（AMR）预防和治疗的协同作用。展望未来，需要关于接受硼替佐米治疗的致敏患者的长期数据，以全面评估这种治疗的影响。
Zotero 插件